News &amp; Updates

Switching to a single-tablet triple-drug combination comprising bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) is well tolerated while continuing to provide virologic suppression through to 48 weeks in elderly people (aged ≥65 years) living with HIV (PLWH), shows a pooled analysis presented at the AIDS 2020 virtual conference.

Switching to B/F/TAF maintains viral suppression in HIV+ elderly

Starting lipid-lowering therapy for ASCVD prevention: How early and in whom?

Intensive cholesterol-lowering therapy yields substantial reductions in the risk of atherosclerotic cardiovascular disease (ASCVD) over a 30-year period. This can be achieved if therapy is initiated in individuals in their 40s and 50s with nonhigh-density lipoprotein cholesterol (non-HDL-C) levels at least 160 mg/dL, according to a team of researchers.

Starting lipid-lowering therapy for ASCVD prevention: How early and in whom?

Charlson Comorbidity Index a valuable tool in estimating renal cell carcinoma prognosis

Use of the Charlson Comorbidity Index (CCI) appears to be beneficial for assessing prognosis and optimizing therapy in patients with advanced renal cell carcinoma who are receiving first-line sunitinib or pazopanib, suggests a recent study.

Charlson Comorbidity Index a valuable tool in estimating renal cell carcinoma prognosis

Statins may protect against C. difficile infections

Use of statins appears to confer a protective benefit against the development of Clostridium difficile infection (CDI) and improve CDI treatment success, according to a study. However, its benefit on mortality remains unclear.

Statins may protect against C. difficile infections

HIV does not worsen COVID-19 outcomes

People living with HIV (PLWH) who are hospitalized for COVID-19 are not more likely to die than those without HIV despite having comorbidities associated with worse COVID-19 outcomes, a US study has shown.

HIV does not worsen COVID-19 outcomes

Personalized TAK-660 prophylaxis may prevent bleeds in severe haemophilia A

Findings from the PROPEL* trial presented at ISTH 2020 suggest that a personalized prophylaxis with rurioctocog alfa pegol (TAK-660) may prevent bleeds in patients with severe haemophilia A.

Personalized TAK-660 prophylaxis may prevent bleeds in severe haemophilia A

Apixaban tied to lower VTE risk in ambulatory cancer patients

Treatment with apixaban led to a significantly reduced risk of venous thromboembolism (VTE) among ambulatory cancer patients who were undergoing chemotherapy, according to two post hoc analyses of the AVERT* trial presented at the ISTH 2020 Meeting.

Apixaban tied to lower VTE risk in ambulatory cancer patients

Flu vaccine may reduce CV risk in high-risk individuals

12 Aug 2020 by

Individuals at high risk for influenza who receive an influenza vaccination may have a reduced risk of cardiovascular (CV) events, according to a retrospective study presented at BCVS* 2020.

Flu vaccine may reduce CV risk in high-risk individuals

Hormone replacement therapy improves bone mass of women after HSCT

Early and active hormonal therapy confers benefits for bone mineral density (BMD) in female patients with premature ovarian insufficiency (POI) who underwent allogeneic haematopoietic stem cell transplantation (HSCT), a recent study has found.

Hormone replacement therapy improves bone mass of women after HSCT

Selected antidepressants may be bad for bones in older women

Use of antidepressants in older women has been linked to cortical bone and physical function deterioration, effects that are specific to selective serotonin reuptake inhibitors (SSRIs) and serotonin norepinephrine reuptake inhibitors (SNRIs), a study has found.

Selected antidepressants may be bad for bones in older women